These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35747969)

  • 1. Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent.
    Patel P; Wahan SK; Vishakha S; Kurmi BD; Gupta GD; Rajak H; Asati V
    Curr Cancer Drug Targets; 2022; 23(1):47-70. PubMed ID: 35747969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics-based trapping with single or multiple inactive mutants reproducibly profiles histone deacetylase 1 substrates.
    Herath KE; Kodikara IKM; Pflum MKH
    J Proteomics; 2023 Mar; 274():104807. PubMed ID: 36587730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
    Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
    PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
    Li X; Xu W
    Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
    Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
    Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
    Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
    Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
    Lee AY; Paweletz CP; Pollock RM; Settlage RE; Cruz JC; Secrist JP; Miller TA; Stanton MG; Kral AM; Ozerova ND; Meng F; Yates NA; Richon V; Hendrickson RC
    J Proteome Res; 2008 Dec; 7(12):5177-86. PubMed ID: 19367703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
    Jang YG; Ko EB; Choi KC
    J Nutr Biochem; 2020 Oct; 84():108444. PubMed ID: 32615369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluid-electrolyte homeostasis requires histone deacetylase function.
    Hyndman KA; Speed JS; Mendoza LD; Allan JM; Colson J; Sedaka R; Jin C; Jung HJ; El-Dahr S; Pollock DM; Pollock JS
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32673289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
    Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
    Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.